These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27966453)

  • 1. Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.
    Dobson CC; Naing T; Beug ST; Faye MD; Chabot J; St-Jean M; Walker DE; LaCasse EC; Stojdl DF; Korneluk RG; Holcik M
    Oncotarget; 2017 Jan; 8(2):3495-3508. PubMed ID: 27966453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression.
    Beug ST; Pichette SJ; St-Jean M; Holbrook J; Walker DE; LaCasse EC; Korneluk RG
    Mol Ther Oncolytics; 2018 Sep; 10():28-39. PubMed ID: 30101187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.
    Petak I; Douglas L; Tillman DM; Vernes R; Houghton JA
    Clin Cancer Res; 2000 Oct; 6(10):4119-27. PubMed ID: 11051265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.
    Xu N; Hua Z; Ba G; Zhang S; Liu Z; Thiele CJ; Li Z
    J Exp Clin Cancer Res; 2019 Mar; 38(1):118. PubMed ID: 30850026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.
    Kim DS; Dastidar H; Zhang C; Zemp FJ; Lau K; Ernst M; Rakic A; Sikdar S; Rajwani J; Naumenko V; Balce DR; Ewanchuk BW; Tailor P; Yates RM; Jenne C; Gafuik C; Mahoney DJ
    Nat Commun; 2017 Aug; 8(1):344. PubMed ID: 28839138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
    Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
    Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1.
    Faye MD; Beug ST; Graber TE; Earl N; Xiang X; Wild B; Langlois S; Michaud J; Cowan KN; Korneluk RG; Holcik M
    Oncogene; 2015 Mar; 34(12):1532-41. PubMed ID: 24704827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.
    Cai J; Lin Y; Zhang H; Liang J; Tan Y; Cavenee WK; Yan G
    Proc Natl Acad Sci U S A; 2017 Jun; 114(26):6812-6817. PubMed ID: 28607091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma.
    Camero S; Milazzo L; Vulcano F; Ceccarelli F; Pontecorvi P; Pedini F; Rossetti A; Scialis ES; Gerini G; Cece F; Pomella S; Cassandri M; Porrazzo A; Romano E; Festuccia C; Gravina GL; Ceccarelli S; Rota R; Lotti LV; Midulla F; Angeloni A; Marchese C; Marampon F; Megiorni F
    BMC Cancer; 2024 Jul; 24(1):814. PubMed ID: 38977944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
    Selman M; Rousso C; Bergeron A; Son HH; Krishnan R; El-Sayes NA; Varette O; Chen A; Le Boeuf F; Tzelepis F; Bell JC; Crans DC; Diallo JS
    Mol Ther; 2018 Jan; 26(1):56-69. PubMed ID: 29175158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells.
    Petak I; Vernes R; Szucs KS; Anozie M; Izeradjene K; Douglas L; Tillman DM; Phillips DC; Houghton JA
    Cell Death Differ; 2003 Jun; 10(6):729-39. PubMed ID: 12761581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma.
    Rodeberg DA; Erskine C; Celis E
    J Pediatr Surg; 2007 Aug; 42(8):1396-402. PubMed ID: 17706503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.
    Bourgeois-Daigneault MC; St-Germain LE; Roy DG; Pelin A; Aitken AS; Arulanandam R; Falls T; Garcia V; Diallo JS; Bell JC
    Breast Cancer Res; 2016 Aug; 18(1):83. PubMed ID: 27503504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer.
    Ge Y; Lei W; Ma Y; Wang Y; Wei B; Chen X; Ru G; He X; Mou X; Wang S
    Mol Med Rep; 2017 Jun; 15(6):3521-3528. PubMed ID: 28440486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
    Shekhar TM; Burvenich IJG; Harris MA; Rigopoulos A; Zanker D; Spurling A; Parker BS; Walkley CR; Scott AM; Hawkins CJ
    BMC Cancer; 2019 Sep; 19(1):924. PubMed ID: 31521127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A; Hugle M; Fulda S
    Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models.
    Chen CY; Wang PY; Hutzen B; Sprague L; Swain HM; Love JK; Stanek JR; Boon L; Conner J; Cripe TP
    Sci Rep; 2017 May; 7(1):2396. PubMed ID: 28539588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.
    Beug ST; Beauregard CE; Healy C; Sanda T; St-Jean M; Chabot J; Walker DE; Mohan A; Earl N; Lun X; Senger DL; Robbins SM; Staeheli P; Forsyth PA; Alain T; LaCasse EC; Korneluk RG
    Nat Commun; 2017 Feb; 8():. PubMed ID: 28198370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
    Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
    Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
    van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
    Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.